INTRODUCTION
The incidence of testicular cancer has been rising steadily since the early years of this century, and it is now the commonest form of cancer in men aged [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] (Davies, 1981) . In the United Kingdom it affects approximately one man in 500 before the age of 50. However, during the past few years the prognosis for these patients has improved substantially chiefly as a result of the introduction of effective chemotherapy especially the drug cisplatin, and also because of improved clinical staging procedures, and the development of rapid, sensitive radioimmunoassay techniques for the measurement of the tumour markers a-foetoprotein (AFP) and human chorionic gonadotrophin (hCG). Bureau, 1981) indicate an annual incidence of testicular cancer similar to the overall national figure, i.e. 3.3 per 100,000 males. However, our own more recent data indicate that the incidence is now significantly greater than this ( Figure 1 ) and continues to increase, having almost doubled in incidence since that time. 
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Serai 1968-1972 1973-1977 1978-1982 Figure 1 The value of this study will increase as the information obtained is collated and analysed, and we will be able to compare our own data with that of other workers in this field. Figure 2 Serum j3hCG values in a seminoma patient pre-and post-orchidectomy. The 
